secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-020869
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel Therapeutics Q1 net loss $8.8M; cash runway into Q2 2024; fast track for CAN-2409 in NSCLC
--------------------------------------------------------------------------------

- Net loss of $8.8M in Q1 2023 vs $0.9M in Q1 2022; includes $0.8M other income from warrant liability change.
- Cash and equivalents $59.3M; expected to fund operations into Q2 2024.
- FDA granted fast track designation for CAN-2409 in stage III/IV NSCLC resistant to PD-(L)1 therapy.
- Paused enrollment in phase 2 pancreatic cancer trial pending additional funding; initial data still expected Q4 2023.
- Upcoming data: CAN-3110 at ASGCT (May 19) and CAN-2409 NSCLC trial-in-progress at ASCO (June 4).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000095017023020869/0000950170-23-020869-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000095017023020869/cadl-20230511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-020869

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer